Earli, Inc.
Earli is dedicated to transforming cancer detection and treatment through innovative genetic constructs that turn on exclusively in cancer cells, enabling early detection and self-destruction of tumors. Their mission is to make cancer a benign experience by turning cancer against itself, leveraging cutting-edge science, engineering, and software. The company has a strong focus on early cancer detection, synthetic biomarkers, and turning cancer into a factory for therapeutic proteins, aiming to extend patients' lives and improve outcomes.
Industries
Nr. of Employees
small (1-50)
Earli, Inc.
Products
Synthetic Biopsy
A technology developed by Earli that biologically forces cancer cells to produce synthetic biomarkers, making them directly localizable in a PET scan for early cancer detection.
Cancer Localization Technology
Utilizes synthetic biomarkers produced by cancer cells to precisely locate early-stage tumors within the body, enabling targeted treatment.
Clinical Trials
Earli conducts clinical trials to test the safety and efficacy of its Synthetic Biopsy technology in detecting and localizing cancer at early stages.
Canine Cancer Research
Research conducted in collaboration with UC Davis to test Earli's technology in dogs with naturally occurring cancer, contributing to both human and veterinary oncology.
Synthetic Biopsy
A technology developed by Earli that biologically forces cancer cells to produce synthetic biomarkers, making them directly localizable in a PET scan for early cancer detection.
Cancer Localization Technology
Utilizes synthetic biomarkers produced by cancer cells to precisely locate early-stage tumors within the body, enabling targeted treatment.
Clinical Trials
Earli conducts clinical trials to test the safety and efficacy of its Synthetic Biopsy technology in detecting and localizing cancer at early stages.
Canine Cancer Research
Research conducted in collaboration with UC Davis to test Earli's technology in dogs with naturally occurring cancer, contributing to both human and veterinary oncology.